From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV

Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Viread® (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12. The FDA approved a supplemental New Drug Application (sNDA) for three lower-strength once-daily tablets of Viread in doses of 150 mg, 200 mg and 250 mg for children ages 6-12.

The agency also approved a New Drug Application for an oral powder formulation of Viread for children ages 2-5. The active ingredient in Viread, tenofovir disoproxil fumarate, is currently the most-prescribed molecule for adults receiving HIV therapy in the United States.